Lido Advisors LLC Purchases Shares of 55,465 IDEAYA Biosciences, Inc. $IDYA

Lido Advisors LLC purchased a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 55,465 shares of the company’s stock, valued at approximately $1,913,000. Lido Advisors LLC owned 0.06% of IDEAYA Biosciences at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its holdings in IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after purchasing an additional 580 shares during the period. ANTIPODES PARTNERS Ltd boosted its holdings in IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in IDEAYA Biosciences in the 3rd quarter valued at $38,000. Global Retirement Partners LLC bought a new stake in IDEAYA Biosciences in the 4th quarter valued at $61,000. Finally, Abich Financial Wealth Management LLC bought a new stake in IDEAYA Biosciences in the 3rd quarter valued at $58,000. 98.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IDYA shares. Royal Bank Of Canada increased their price target on shares of IDEAYA Biosciences from $49.00 to $53.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Wall Street Zen cut shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Wells Fargo & Company increased their price objective on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. Wedbush restated an “outperform” rating and issued a $58.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, June 2nd. Finally, Mizuho dropped their price objective on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Fifteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $50.69.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $31.48 on Tuesday. IDEAYA Biosciences, Inc. has a 52-week low of $20.50 and a 52-week high of $39.28. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of -19.68 and a beta of -0.04. The firm has a fifty day moving average of $30.18 and a 200-day moving average of $32.62.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The firm had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period last year, the company posted ($0.82) EPS. The business’s quarterly revenue was down 39.4% on a year-over-year basis. On average, sell-side analysts predict that IDEAYA Biosciences, Inc. will post -4.27 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.